NPM1 and neoplasm: Additionally, PD‐L1 is overexpressed during malignancy for reasons of oncogenic driver events, such as epidermal growth factor receptor mutations, phosphatase‐tensin homolog (PTEN) mutations, and nucleophosmin (NPM)/anaplastic lymphoma kinase gene fusion, usually indicating a poor prognosis of tumor progression.13, 14, 15